[go: up one dir, main page]

NO20060165L - Anvendelse av prionkonverteringsmodulerende midler - Google Patents

Anvendelse av prionkonverteringsmodulerende midler

Info

Publication number
NO20060165L
NO20060165L NO20060165A NO20060165A NO20060165L NO 20060165 L NO20060165 L NO 20060165L NO 20060165 A NO20060165 A NO 20060165A NO 20060165 A NO20060165 A NO 20060165A NO 20060165 L NO20060165 L NO 20060165L
Authority
NO
Norway
Prior art keywords
modulating agents
apolipoprotein
prion
prion conversion
conversion modulating
Prior art date
Application number
NO20060165A
Other languages
English (en)
Other versions
NO338179B1 (no
Inventor
Claudio Soto-Jara
Kinsey Maundrell
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20060165L publication Critical patent/NO20060165L/no
Publication of NO338179B1 publication Critical patent/NO338179B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Anvendelse av Apolipoprotein B, Apolipoprotein E, fragmenter og hermere derav er tilveiebrakt for diagnose, deteksjon, prognose og terapeutisk anvendelse i prionsykdommer. Mer spesifikt tilveiebringer oppfmnelsen anvendelsen av Apolipoprotein B eller fragmenter derav til å modulere eller identifisere modulatorer av prion proteinreplikasjon som er implisert i patogenesen til overførbar spongioform encefalopati og andre prionsykdommer.
NO20060165A 2003-06-19 2006-01-11 Anvendelse av prionkonverteringsmodulerende midler NO338179B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101795 2003-06-19
PCT/EP2004/051170 WO2004111652A1 (en) 2003-06-19 2004-06-18 Use of prion conversion modulating agents

Publications (2)

Publication Number Publication Date
NO20060165L true NO20060165L (no) 2006-01-11
NO338179B1 NO338179B1 (no) 2016-08-01

Family

ID=33547743

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060165A NO338179B1 (no) 2003-06-19 2006-01-11 Anvendelse av prionkonverteringsmodulerende midler

Country Status (9)

Country Link
US (2) US7598046B2 (no)
EP (1) EP1636592B1 (no)
JP (1) JP5133561B2 (no)
AU (2) AU2004248302B2 (no)
CA (1) CA2525517C (no)
ES (1) ES2401645T3 (no)
IL (1) IL172354A (no)
NO (1) NO338179B1 (no)
WO (1) WO2004111652A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216788B2 (en) * 2007-07-20 2012-07-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Detection of infectious prion protein by seeded conversion of recombinant prion protein
WO2015160007A1 (ko) * 2014-04-17 2015-10-22 한림대학교 산학협력단 극미량 병원성 프리온 단백질 검출방법 및 장치
EP3142386B1 (en) * 2015-09-08 2019-04-24 Oticon A/s Sealing earpiece
EP3463416A1 (en) 2016-05-31 2019-04-10 CardioVax, LLC Methods for diagnosing and treating systemic lupus erythematosus
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CA3038045C (en) * 2017-10-13 2020-11-24 Uti Limited Partnership Products and methods associated with multiple sclerosis as a transmissible protein misfolding disorder
EP4175588A4 (en) 2020-07-06 2024-10-16 Perfect Fit Crowns, LLC METHOD AND DEVICE FOR RESTORATION OF DENTAL CROWNS USING PREFABRICATED SLEEVE CROWN PAIRS

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278059A (en) * 1985-12-04 1994-01-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaki Kenkyujo Polypeptide possessing cyclomaltodextrin glucanotransferase activity
US5134121A (en) * 1988-03-28 1992-07-28 Regents Of The University Of California Nerve growth factor peptides
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
TW457240B (en) 1995-04-20 2001-10-01 Janssen Pharmaceutica Nv Novel triazolones as apolipoprotein-B synthesis inhibitors
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
CA2233848A1 (en) 1995-10-17 1997-04-24 The Regents Of The University Of California Methods of reducing apolipoprotein e4-induced inhibition of neuron remodeling
JPH10239313A (ja) * 1997-02-27 1998-09-11 Dai Ichi Pure Chem Co Ltd ヘパリン親和性物質の測定方法
JP2001517617A (ja) 1997-09-24 2001-10-09 ノヴァ モレキュラー インク． 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法
US6506880B2 (en) * 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
JP2002530122A (ja) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
IL139217A0 (en) 2000-03-13 2001-11-25 Applied Research Systems Monoclonal antibodies to the human ldl receptor, their production and use
US6335610B1 (en) * 2000-06-30 2002-01-01 Ford Global Technologies, Inc. Method and apparatus for determining the operational energy cost of a hybrid vehicle
NZ523213A (en) 2000-07-07 2005-01-28 Applied Research Systems Early diagnosis of conformational diseases
DE10107083C2 (de) * 2001-02-13 2003-02-20 Abdulgabar Salama Pentosan Polysulfat als Ligand zum Nachweis von Prionen
DE20105791U1 (de) * 2001-04-03 2002-08-14 MEKRA Lang GmbH & Co. KG, 90765 Fürth Spiegelanordnung für Kraftfahrzeuge
JP2002323662A (ja) * 2001-04-24 2002-11-08 Furukawa Electric Co Ltd:The 光フィルタの角度調整装置、角度調整方法及び光モジュール
US20040018554A1 (en) * 2001-05-15 2004-01-29 Green Larry R. Methods and compositions for detection of bovine spongiform encephalopathy and variant creutzfeldt-jacob disease
TNSN03146A1 (fr) 2001-06-28 2005-12-23 Pfizer Prod Inc Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipo-proteine b (apo b).
FR2827047B1 (fr) * 2001-07-03 2003-09-26 Apoh Technollgies Sa Procede de separation et/ou detection et/ou identification et/ou quantification de proteines prions
CA2468716A1 (en) 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
WO2004043403A2 (en) 2002-11-13 2004-05-27 The Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use

Also Published As

Publication number Publication date
ES2401645T3 (es) 2013-04-23
JP5133561B2 (ja) 2013-01-30
CA2525517C (en) 2016-05-31
CA2525517A1 (en) 2004-12-23
EP1636592B1 (en) 2012-12-19
AU2004248302B2 (en) 2009-07-30
NO338179B1 (no) 2016-08-01
EP1636592A1 (en) 2006-03-22
US20090317380A1 (en) 2009-12-24
JP2007527504A (ja) 2007-09-27
AU2004248302A1 (en) 2004-12-23
AU2009232094A1 (en) 2009-11-19
US20070020682A1 (en) 2007-01-25
IL172354A (en) 2011-12-29
WO2004111652A1 (en) 2004-12-23
US7598046B2 (en) 2009-10-06

Similar Documents

Publication Publication Date Title
Leonardi et al. Ocular surface expression of SARS-CoV-2 receptors
Devaux et al. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome
Bingham III et al. Periodontal disease and rheumatoid arthritis: the evidence accumulates for complex pathobiologic interactions
BRPI0410348A (pt) compostos e usos dos mesmos na modulação de amilóide-beta
WO2008069975A3 (en) Methods of using f-spondin as a biomarker for cartilage degenerative conditions
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
DE602004028590D1 (de) Gerät zur wiederherstellung der aortenklappe und dieses verwendende behandlungsverfahren
NO20083044L (no) Deteksjon av loselige adisponektinreseptorpeptider og anvendelse i diagnostikk og terapi
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
Rashid et al. Functional up‐regulation of endopeptidase neurolysin during post‐acute and early recovery phases of experimental stroke in mouse brain
NO20060165L (no) Anvendelse av prionkonverteringsmodulerende midler
NO20071018L (no) Kombinasjonsbehandling ved a anvende fusjonsproteiner omfattende GLP-1
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
ECSP088254A (es) Compuestos activos en ppar
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
MX364874B (es) Anticuerpos de il-6 y uso de los mismos.
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
CY1113403T1 (el) Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων
CY1113214T1 (el) Φαρμακευτικη συνθεση
EA200601760A1 (ru) Тетрагидроиндазольные модуляторы каннабиноидов
EP1395285A4 (en) REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS
Hung et al. Beyond malignancy: the role of carbohydrate antigen 125 in heart failure
ATE249046T1 (de) Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können
WO2003103613A3 (en) Induction of insulin expression

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS